Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
Sandler
M
M
Bernhard Baron Memorial Research Laboratories, Queen Charlotte's and Chelsea Hospital, London, United Kingdom.
Glover
V
V
Clow
A
A
Jarman
J
J
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology*; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008995:Monoamine Oxidase / Q000502:physiology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010300:Parkinson Disease / Q000503:physiopathology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology; D013482:Superoxide Dismutase / Q000502:physiology*
D008996:Monoamine Oxidase Inhibitors; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D013482:Superoxide Dismutase; D008995:Monoamine Oxidase